news
Ablynx expands its immuno-oncology collaboration with MSD
22 July 2015 | By Victoria White
Ablynx has expanded its immuno-oncology collaboration with MSD to address an increased number of immune checkpoint modulator targets...
List view / Grid view
MSD
news
MSD, Illumina and Genea form the Global Fertility Alliance
8 June 2015 | By Victoria White
The Global Fertility Alliance is a new collaboration to advance excellence in fertility technologies within the assisted reproductive treatment laboratory...
news
MSD extends immuno-oncology collaboration with Agenus
3 June 2015 | By Victoria White
MSD has extended its existing collaborative research agreement with Agenus for the discovery and development of therapeutic antibodies...
news
Plexxikon and MSD team up to evaluate PLX3397 in combination with KEYTRUDA
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
news
Arvinas announces multi-year collaboration with MSD to study protein degradation technology
8 April 2015 | By Victoria White
Arvinas to collaborate with MSD to use PROTAC technology to degrade target proteins, with the goal of creating novel therapeutics...
news
MSD and Intrexon announce agreement for the development and commercialisation of CAR-T cancer therapy
31 March 2015 | By Victoria White
Merck Serono and Intrexon Corporation have announced an exclusive collaboration and license agreement to develop and commercialise CAR-T cancer therapies...
news
NICE issues guidance on biologic treatments for ulcerative colitis
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
news
UK patients with moderately to severely active ulcerative colitis gain access to a range of biologic therapies on the NHS
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
news
Pfizer and MSD to collaborate on study evaluating novel anti-cancer combination regimen
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
news
MSD begins tender offer to acquire Idenix
23 June 2014 | By Merck
MSD is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
news
MSD to acquire Idenix
9 June 2014 | By Merck
MSD and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which MSD will acquire Idenix for $24.50 per share in cash...
news
First patient enrolled in new Phase 3 trial program investigating a once-daily dosing regimen of ISENTRESS® (raltegravir)
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
news
MSD and Endocyte announce independent DSMB recommends vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis
2 May 2014 | By Merck
MSD and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
news
MSD announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...
news
MSDand Samsung Bioepis enter collaboration agreement to develop and commercialize insulin glargine candidate for diabetes
11 February 2014 | By Merck
MSD and Samsung Bioepis Co., Ltd., announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293...